In fact, Eriksson et al. reported that targeting FLT3 signaling with the FLT3i AKN-028 or midostaurin for 12–48 h triggered G1 phase arrest in FLT3-mutated MV4–11 AML cells as well (40). Here, FLT3 is linked to acute myeloid leukemia.